Peripheral Artery Disease
Lack of Lp(a) screening a ‘missed opportunity’; promising therapies on the horizon
Improved screening for elevated lipoprotein(a) levels among all adults may improve CVD risk assessment and outcomes, especially with multiple Lp(a)-lowering therapies currently in the research pipeline, a speaker reported.
First investigational oral therapy lowers Lp(a) in phase 2 study
CHICAGO — Adults with elevated liproprotein(a) at high risk for a CV event saw substantial reductions over 12 weeks with muvalaplin, an investigational oral small molecule Lp(a) inhibitor, data from a phase 2 study show.
Platelet reactivity score may predict heart attack, stroke risk beyond BP, cholesterol
A platelet reactivity score that identifies people with a hyperreactive platelet phenotype can be used to determine those who might be at elevated risk for a cardiovascular event, researchers reported in Nature Communications.
New PAD guideline endorses multispecialty care team, structured exercise programs
A new guideline on lower-extremity peripheral artery disease encouraged managing care with a multispecialty team and having patients undergo structured exercise programs.
Ultrasound-guided angioplasty beneficial in symptomatic peripheral artery disease
ATLANTA — IVUS-guided angioplasty was superior to an angiography-guided approach for improving immediate procedural outcomes and 12-month patency in patients with symptomatic femoropopliteal artery disease, a speaker reported.
FDA approves novel bioresorbable scaffold for treating chronic limb-threatening ischemia
Abbott announced the FDA has approved its novel below-the-knee, bioresorbable, drug-eluting scaffold for people with chronic limb-threatening ischemia.
Light to moderate alcohol consumption associated with lower risk for PAD
Researchers found a U-shaped association between alcohol consumption and risk for peripheral artery disease, with the lowest risk seen with consuming two drinks per week and more pronounced risk with at least 10 drinks, study data showed.
Climbing stairs reduces risk for all-cause, cardiovascular death
In a meta-analysis of studies covering more than 400,000 people, climbing stairs was associated with reduced risk for all-cause mortality and death from heart disease.
‘Inclisiran-first’ strategy yields greater LDL reductions vs. usual care for patients with CVD
ATLANTA — For patients with atherosclerotic CVD, an inclisiran-first strategy was associated with greater lowering of LDL compared with the usual care, researchers reported at the American College of Cardiology Scientific Session.
ACC to showcase ‘exceptional’ science, mark 75 years at upcoming scientific session
The 2024 American College of Cardiology Scientific Session will be held live in Atlanta from April 6 to 8 and virtually, with 43 late-breaking trials and featured clinical research presentations.